Detalles de la búsqueda
1.
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
; 149(2): 403-408, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33709428
2.
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Oncologist
; 26(9): e1514-e1525, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973293
3.
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Oncologist
; 26(9): e1508-e1513, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33942954
4.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 379(4): 341-351, 2018 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863979
5.
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
Cancer Immunol Immunother
; 70(3): 763-772, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32989552
6.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910338
7.
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Gynecol Oncol
; 159(2): 322-328, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32917410
8.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31563517
9.
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Br J Cancer
; 120(2): 165-171, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420614
10.
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Invest New Drugs
; 37(4): 722-730, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30591982
11.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Br J Clin Pharmacol
; 85(3): 530-539, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30428505
12.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533458
13.
Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma.
Oncologist
; 23(1): 118-120, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158368
14.
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Oncologist
; 23(6): 658-e72, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29511132
15.
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
BMC Cancer
; 18(1): 790, 2018 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30081867
16.
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Br J Clin Pharmacol
; 84(1): 112-121, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28865153
17.
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Br J Cancer
; 116(5): 575-583, 2017 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152546
18.
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Br J Haematol
; 173(6): 884-95, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27071340
19.
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Invest New Drugs
; 34(2): 216-24, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26924128
20.
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Invest New Drugs
; 32(4): 653-60, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24604265